UPDATE: Morgan Stanley Upgrades iRhythm Technologies (IRTC) to Overweight

(Updated - January 18, 2022 4:53 AM EST)

Morgan Stanley analyst Cecilia Furlong upgraded iRhythm Technologies (NASDAQ: IRTC) from Equalweight to Overweight with a price target of $167.00 (from $129.00).

The analyst comments "Novitas' improved rate coupled with constructive CMS national pricing outlook removes the primary stock overhang, setting the stage for a more favorable reimbursement landscape starting 2023. Zio XT is proven cost effective and we continue to believe the technology provides significant value to the healthcare system. Fundamentals and volume growth remain sound and 2022 is shaping up to be crowded year of catalysts."

For an analyst ratings summary and ratings history on iRhythm Technologies click here. For more ratings news on iRhythm Technologies click here.

Shares of iRhythm Technologies closed at $141.10 yesterday.

You May Also Be Interested In

• Tharisa Plc (THS:LN) PT Lowered to GBP2.50 at Berenberg
• Sharp Corp. (6753:JP) (SHCAY) PT Lowered to JPY950 at Citi
• Citi Upgrades Sysmex Corporation (6869:JP) (SSMXY) to Buy